Deletion of phosphodiesterase 4D in mice shortens α2-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis

Journal of Clinical Investigation

Volumn 110, Issue 7, 2002, Pages 1045-1052

  Robichaud, Annette ^a   Stamatiou, Panagiota B ^a   Jin, S L Catherine ^b   Lachance, Nicholas ^a   MacDonald, Dwight ^a   Laliberté, France ^a   Liu, Susana ^a   Huang, Zheng ^a   Conti, Marco ^b   Chan, Chi Chung ^a  

^a MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,3,4,5',6,6',7,12B OCTAHYDRO 1',3' DIMETHYL 2H SPIRO[BENZO[B]FURO[2,3 A]QUINOLIZINE 2,4' PYRIMIDINE] 2' ONE; 6 (4 PYRIDYLMETHYL) 8 (3 NITROPHENYL)QUINOLINE; ALPHA 2 ADRENERGIC RECEPTOR; CYCLIC AMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; KETAMINE; N [4 [1 (3 CYCLOPENTYLOXY 4 METHOXYPHENYL) 2 (4 PYRIDYL)ETHYL]PHENYL] N' ETHYLUREA; PENTOBARBITAL; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV INHIBITOR; QUINOLINE DERIVATIVE; ROLIPRAM; UNCLASSIFIED DRUG; XYLAZINE;

ANESTHESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR; ENZYME ANALYSIS; ENZYME DEFICIENCY; ENZYME INHIBITION; IC 50; MALE; MOUSE; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SLEEP TIME; VOMITING;

EID: 0036790480     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI0215506     Document Type: Article

References (39)

1. Giembycz, M.A. 2001. Cilomilast: a second generation phosphodiesterase 4 inhibitor for asthma and chronic obstructive pulmonary disease. Expert Opin. Investig. Drugs. 10:1361-1379.
2. Essayan, D.M. 2001. Cyclic nucleotide phosphodiesterases. J. Allergy Clin. Immunol. 108:671-680.
3. Timmer, W., et al. 2002. The new phosphodiesterase 4 inhibitor roflumilast is efficacious in exercise-induced asthma and leads to suppression of LPS-stimulated TNF-α ex vivo. J. Clin. Pharmacol. 42:297-303.
4. Torphy, T.J., et al. 1999. Ariflo™ (SB 207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: from concept to clinic. Pulm. Pharmacol. Ther. 12:131-135.
5. Horowski, R., and Sastre-y-Hernandez, M. 1985. Clinical effects of neurotropic selective cAMP phosphodiesterase inhibitor rolipram in depressed patients: global evaluation of the preliminary reports. Current Therapeutic Research. 38:23-29.
6. Humpel, M., Kühne, G., Lehmann, M., and Poggel, A. 1986. Pharmacokinetically governed design of animal toxicity studies of a new antidepressant drug. Arch. Toxicol. 9(Suppl.):251. (Abstr.)
7. Heaslip, R.J., and Evans, D.Y. 1995. Emetic, central nervous system and pulmonary activities of rolipram in the dog. Eur. J. Pharmacol. 286:281-290.
8. Silvestre, J., Graul, A., and Castañer, J. 1998. SB-207499. Antiasthmatic/antiinflamatory, phosphodiesterase IV inhibitor. Drugs of the Future. 23:607-615.
9. Robichaud, A., Tattersall, F.D., Choudhury, I., and Rodger, I.W. 1999. Emesis induced by inhibitors of type IV cyclic nucleotide phosphodiesterase (PDE IV) in the ferret. Neuropharmacology. 38:289-297.
10. Xu, R.X., et al. 2000. Atomic structure of PDE4: insights into phosphodiesterase mechanism and specificity. Science. 288:1822-1825.
11. Laliberté, F., et al. 2000. Conformational difference between PDE4 apoenzyme and holoenzyme. Biochemistry. 39:6449-6458.
12. Liu, S., et al. 2001. Dissecting the cofactor-dependent and independent bindings of PDE4 inhibitors. Biochemistry. 40:10179-10186.
13. Barnette, M.S. 1999. Phosphodiesterase 4 (PDE4) inhibitors in asthma and chronic obstructive pulmonary disease (COPD). Prog. Drug Res. 53:193-229.
14. Barnette, M.S., and Underwood, D.C. 2000. New phosphodiesterase inhibitors as therapeutics for the treatment of chronic lung disease. Curr. Opin. Pulm. Med. 6:164-169.
15. Christensen, S.B., et al. 1998, 1,4-Cyclohexanecarboxylates: potent and selective inhibitors of phosphodiesterase 4 for the treatment of asthma. J. Med. Chem. 41:821-835.
16. Conti, M., and Jin, S.-L.C. 2000. The molecular biology of cyclic nucleotide phosphodiesterases. Prog. Nucleic Acid Res. Mol. Biol. 63:1-38.
17. Robichaud, A., Savoie, C., Scamatiou, P.B., Tattersall, F.D., and Chan, C.C. 2001. PDE4 inhibitors induce emesis in ferrets via a noradrenergic pathway (erratum 2001, 40:465). Neuropharmacology. 40:262-269.
18. 2 agonist in the rat. J. Pharmacol. Exp. Ther. 263:1046-1049.
19. Robichaud, A., et al. 2002. Assessing the emetic potential of PDE4 inhibitors in rats. Br. J. Pharmacol. 135:113-118.
20. Jin, S.-L. C., Richard, F.J., Kuo, W.-P., D'Ercole, A.J., and Conti, M. 1999. Impaired growth and fertility of cAMP-specific phosphodiesterase PDE4D-deficient mice. Proc. Natl. Acad. Sci. USA. 96:11998-12003.
21. Jin, S.-L.C., and Conti, M. 2002. Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-α responses. Proc. Natl. Acad. Sci. USA. 99:7628-7633.
22. Sette, C., Iona, S., and Conti, M. 1994. Short-term activation of a rolipram-sensitive, cAMP specific phosphodiesterase by thyroid-stimulating hormone in thyroid FRTL-5 cells is mediated by a cAMP-dependent phosphorylation. J. Biol. Chem. 269:9245-9252.
23. Iona, S., et al. 1998. Characterization of the rolipram-sensitive, cyclic AMP specific phosphodiesterases: identification and differential expression of immunologically distinct forms in the rat brain. Mol. Pharmacol. 53:23-32.
24. Wilhelm, R.S., Fatheree, P.R., and Chin, R.L., inventors; Syntex (USA) Inc., assignee. October 13, 1994. Quinolines as type IV phosphodiesterase inhibitors. World patent W09422852.
25. Alexander, R.P., et al. 2002. CDP840. A prototype of a novel class of orally active anti-inflammatory phosphodiesterase 4 inhibitors. Bioorg. Med. Chem. Lett 12:1451-1456.
26. Brideau, C., Van Staden, C., Styhler, A., Rodger, I.W., and Chan, C.-C. 1999. The effect of phosphodiesterase type 4 inhibitors on tumor necrosis factor-α and leukotriene B4 in a novel human whole blood assay. Br. J. Pharmacol. 126:979-988.
27. 2-adrenoceptor antagonist, L-657,743. Naunyn Schmiedebergs Arch. Pharmacol. 336:169-175.
28. Fawcett, L., et al. 2000. Molecular cloning and characterization of a distinct human phosphodiesterase gene family: PDE11A. Proc. Natl. Acad. Sci. USA. 97:3702-3707.
29. Fish, R.E. 1997. Pharmacology of injectable anesthetics. In Anesthesia and analgesia in laboratory animals. D.F. Kohn, S.K. Wixson, W.J. White, and G.J. Benson, editors. Academic Press. New York, New York, USA. 1-28.
30. 2 agonist, is mediated in the locus coeruleus in rats. Anesthesiology. 76:948-952.
31. Griswold, D.E., et al. 1998. SB 207499 (Ariflo), a second generation phosphodiesterase 4 inhibitor, reduces tumor necrosis factor α and interleukin-4 production in vivo. J. Pharmacol. Exp. Ther. 287:705-711.
32. Muise, E.S., et al. 2002. Comparison of inhibition of ovalbumin-induced bronchoconstriction in guinea pigs and in vitro inhibition of tumor necrosis factor-α formation with phosphodiesterase 4 (PDE4) selective inhibitors. Biochem. Pharmacol. 63:1527-1535.
33. 2Aadrenoceptor to be the subtype mediating the hypnotic response to the highly selective agonist, dexmedetomidine, in the locus coeruleus of the rat. J. Clin. Invest. 98:1076-1080.
34. 2-adrenoceptors in the central nervous system. J. Physiol. Pharmacol. 46:241-258.
35. 2-adrenergic receptor subtype gene expression in rat brain. Mol. Brain Res. 21:133-149.
36. Alvarez, R., et al. 1995. Activation and selective inhibition of a cyclic AMP-specific phosphodiesterase, PDE-4D3. Mol. Pharmacol. 48:616-622.
37. MacKenzie, S.J., et al. 2002. Long PDE4 cAMP specific phosphodiesterases are activated by protein kinase A-mediated phosphorylation of a single serine residue in upstream conserved region 1 (UCR1). Br. J. Pharmacol. 136:421-433.
38. Laliberté, F., et al. 2002. In vitro PKA phosphorylation-mediated human PDE4A4 activation. FEBS Lett. 512:205-208.
39. Marx, D., Tassabehji, M., Heer, S., Huttenbrink, K.-B., and Szelenyi, I. 2002. Modulation of TNF and GM-CSF release from dispersed human nasal polyp cells and human whole blood by inhibitors of different PDE isoenzymes and glucocorticoids. Pulm. Pharmacol. Ther. 15:7-15.